about
Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments.Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl.CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics.Pharmacogenetics of opioids.Pharmacogenomics of methadone maintenance treatment.Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib.ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.Pharmacogenetics of opioid response.Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain.Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study.Association of innate immune single-nucleotide polymorphisms with the electroencephalogram during desflurane general anaesthesia.Corticosterone Preexposure Increases NF-κB Translocation and Sensitizes IL-1β Responses in BV2 Microglia-Like Cells.CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post Kidney Transplantation.Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safetyHigh and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptomsIs There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation
P50
Q33238415-A5DA5108-F598-4966-97B6-9836D4EEBCB6Q35762509-F61F811F-C09C-4D55-A583-EA16AC3D419EQ36229161-12BA4677-A7C0-4216-BA9F-A97CD3D6CE5CQ36441533-0AF0746A-ED14-4E43-940F-E6FA472DB090Q36752672-F68E9EC8-A1D7-486D-B711-71E416751130Q38222510-9B091E8A-91D2-4B59-9B3D-5E35EF3E77ECQ40751644-57E96F7E-8F03-4C23-B38A-5142E30335CFQ44333294-8C8596A8-4E9D-4C3F-9115-B6096423732CQ44349632-2FFBA394-FEDB-4299-AF2D-A1C4F0DBA18DQ47377458-0534C638-8B26-4B6F-9A1C-7411A3BC8259Q47919321-964F1B98-D224-4075-A475-8AB55EB9ED1BQ47935662-9B0937DC-DB9A-41AA-95DF-BD233B329AD0Q49299368-3D22D4B3-91CA-48E2-B8C1-30ACE9210E91Q52617445-AD8D8BAA-EB5F-4B19-8251-892981F0C9ADQ56379671-F84F8055-9D72-4B27-A486-1EECF2D5F7BAQ92805526-F1B3C264-9D1F-45EE-9686-9DE177B12D30Q93157288-F05E59D0-A0BC-45FA-8311-A439FA9857EAQ93390510-288D6984-12BA-44EB-B047-CBB75CF5502F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Daniel Barratt
@ast
Daniel Barratt
@en
Daniel Barratt
@es
Daniel Barratt
@nl
Daniel Barratt
@sl
Даниэль Барратт
@ru
type
label
Daniel Barratt
@ast
Daniel Barratt
@en
Daniel Barratt
@es
Daniel Barratt
@nl
Daniel Barratt
@sl
Даниэль Барратт
@ru
prefLabel
Daniel Barratt
@ast
Daniel Barratt
@en
Daniel Barratt
@es
Daniel Barratt
@nl
Daniel Barratt
@sl
Даниэль Барратт
@ru
P106
P21
P31
P496
0000-0001-6261-353X